

分子標的医学

論文

A 欧文

A-a

1. Mizutani T, Ano T, Yoshioka Y, Mizuta S, Takemoto K, Ouchi Y, Morita D, Kitano S, Miyachi H, Tsuruyama T, Fujiwara N, Sugita M: Neutrophil S100A9 supports M2 macrophage niche formation in granulomas. *iScience* : 106081, 2023. doi: 10.1016/j.isci.2023.106081. (IF: 4.6) *
2. Maki T, Zhou Z, Irie Y, Matsunaga T, Onodera T, Imamichi S, Sasaki Y, Masutani M, Otaki H, Sakuda E, Tanaka Y, Murota H: Singlet-oxygen photosensitizers with a tetrad structure and a single BODIPY chromophore: An evidence for transition state stabilization of intersystem crossing. *Dyes and Pigments* 210: 110963, 2023. doi: 10.1016/j.dyepig.2022.110963. (IF: 4.1) *
3. Mizuta S, Mosaddeque F, Mya Myat N. T, Teklemichael AA, Taniguchi M, Hosokawa M, Yamaguchi T, Makau J, Huy NT, Mizukami S, Nishida N, Morita K, Hirayama K: Challenges Based on Antiplasmodial and Antiviral Activities of 7-Chloro-4-aminoquinoline Derivatives. *ChemMedChem* 18(7): e202200586, 2023. doi: 10.1002/cmdc.202200586. (IF: 3.2) *
4. Hiroki H, Ishii Y, Piao J, Namikawa Y, Masutani M, Honda H, Akahane K, Inukai T, Morio T, Takagi M: Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells. *Scientific Reports* 13(1): 7588, 2023. doi: 10.1038/s41598-023-33852-2. (IF: 3.8) ☆*
5. Perico D, Tong Y, Chen L, Imamichi S, Sanada Y, Ishiai M, Suzuki M, Masutani M, Mauri P: Proteomic Characterization of SAS Cell-Derived Extracellular Vesicles in Relation to Both BPA and Neutron Irradiation Doses.. *Cells* 12(12): 1562, 2023. doi: 10.3390/cells12121562. (IF: 5.1) ☆*
6. Nakamura S, Imamichi S, Shimada K, Takemori M, Kanai Y, Iijima K, Chiba T, Nakayama H, Nakaichi T, Mikasa S, Urago Y, Kashiara T, Takahashi K, Nishio T, Okamoto H, Itami J, Ishiai M, Suzuki M, Igaki H, Masutani M: Relative biological effectiveness for epithermal neutron beam contaminated with fast neutrons in the linear accelerator-based boron neutron capture therapy system coupled to a solid-state lithium target.. *Journal of radiation research* 64(4): 661-667, 2023. doi: 10.1093/jrr/rrad037. (IF: 1.9) *
7. Nakada N, Miyazaki T, Mizuta S, Hirayama T, Nakamichi S, Takeda K, Mukae H, Kohno S, Tanaka Y: Screening and Synthesis of Tetrazole Derivatives that Inhibit the Growth of *Cryptococcus* Species. *ChemMedChem* : e202300157, 2023. doi: 10.1002/cmdc.202300157. (IF: 3.2) *
8. Imamichi S, Chen L, Ito T, Tong Y, Onodera T, Sasaki Y, Nakamura S, Mauri P, Sanada Y, Igaki H, Murakami Y, Suzuki M, Itami J, Masunaga S, Masutani M: Correction: Imamichi et al. Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy. *Biology* 2022, 11, 420.. *Biology* 12(8): 420, 2023. doi: 10.3390/biology12081112. *
9. Mizuta S, Tabira M, Shichiro N, Yamaguchi T, Ishihara J, Ishikawa T: Reaction Mechanism and Origin of Stereoselectivity in the Fluorination and Trifluoromethylthiolation of 2-Bromoamides with AgF and AgSCF₃. *European Journal of Organic Chemistry* : e202301100, 2023. doi: 10.1002/ejoc.202301100. (IF: 3) *
10. Sasaki Y, Nakatsuka R, Inoue A, Inouchi T, Masutani M, Nozaki T: Dysfunction of poly (ADP-ribose) glycohydrolase suppresses osteoclast differentiation in RANKL-stimulated RAW264 cells.. *Biochemical and biophysical research communications* 692: 149309, 2023. doi: 10.1016/j.bbrc.2023.149309. (IF: 2.5)

A-b

1. Masutani M, Miwa M, Poltronieri P: NAD⁺ Consuming Enzymes: Involvement in Therapies and Prevention of Human Diseases.. *Anti-cancer agents in medicinal chemistry* 23(12): 1351-1354, 2023. doi: 10.2174/1871520623666230320153757. (IF: 2.5) *
2. Tran L, Tu VL, Dadam MN, Aziz JMA, Duy TLD, Ahmed HHH, Kwaah PA, Quoc HN, Van Dat T, Mizuta S, Hirayama K, Huy NT: Antimalarial activities of benzothiazole analogs: A systematic review. *Fundamental & Clinical Pharmacology* : 410-464, 2023. doi: 10.1111/fcp.12974.

A-d

1. Tong Y, Gao Z, Saraswat B, Vadi Velu A, Sasaki Y, Ishiai M, Imamichi S, Nozaki T, Suzuki M, Sanada Y, Masutani M: The Response of Tumor Cells to BNCT. *KURNS Progress Report* : 230, 2023.

A-e-1

1. Tong Y, Gao Z, Imamichi S, Sanada Y, Sasaki Y, Nozaki T, Suzuki M, Masunaga S, Masutani M: BNCT後の早期反応バイオマーカーとしてのHMGB1の動的プロファイル(Dynamic profile of HMGB1 as a biomarker for the early response after BNCT). 日本癌学会総会記事 82回: 2156, 2023.
2. Sasaki Y, Masutani M, Nakatsuka R, Inouchi T, Nozaki T: Exploration of olaparib resistance factors in BRCA1 knockout olaparib resistant cancer cells.. 第82回日本癌学会学術総会抄録集(Web) 82nd: 2023.
3. Gao Z, Tong Y, Imamichi S, Sanada Y, Suzuki M, Ishiai M, Masunaga S, Masutani M: The biological analysis of noncoding RNA SNHG12 after boron neutron capture therapy (BNCT). 第82回日本癌学会学術総会抄録集(Web) 82nd: 2023.
4. Hayashi K, Tong Y, Myat AB, Yanagihara K, Nakao K, Masutani M: Synergistic effects of combinational treatment of platinum drugs on gastric cancer cells. 第82回日本癌学会学術総会抄録集(Web) 82nd: 2023.
5. Vadi Velu A, Saraswat B, Tong Y, Myat AB, Matsuno K, Takamura T, Koizumi F, Masutani M: Analysis of cell death processes induced by the potential anti-cancer drug MO2455 in various lymphoma cells.. 第82回日本癌学会学術総会抄録集(Web) 82nd: 2023.
6. Tong Y, Chen L, Gao Z, Imamichi S, Sanada Y, Sasaki Y, Nozakai T, Ishiai M, Suzuki M, Masutani M: The role of GM-CSF in the early response to BNCT. 日本分子生物学会年会プログラム・要旨集(Web) 46th: 2023.
7. Myat AB, Nishiyama I, Tong Y, Masutani M: Unravelling the combined therapeutic effect of PARP and microtubule inhibitors on chromosomal hyperploidy induction and cell cycle arrest. 日本分子生物学会年会プログラム・要旨集(Web) 46th: 2023.
8. Vadi Velu A, Saraswat B, Tong Y, Myat AB, Matsuno K, Takamura T, Koizumi F, Masutani M: Cell death responses induced by a potential anti-cancer agent MO2455 in lymphoma U937 cells. 日本薬学会年会要旨集(Web) 143rd: 2023.
9. Murayama K, Tong Y, Saraswat B, Hayashi K, Masutani M: Development of evaluation model of flow cytometry for combination effects of anti-cancer agents using machine learning. 日本分子生物学会年会プログラム・要旨集(Web) 46th: 2023.
10. Saraswat B, Vadi Velu A, Gao Z, Tong Y, Fujimori H, Hirai T, Masutani M: Radiosensitization effects and mechanism of PARP inhibitors on cancer cells. 日本生化学会大会(Web) 96th: 2023.
11. Vadi Velu A, Saraswat B, Tong Y, Matsuno K, Takamura T, Koizumi F, Masutani M: Therapeutic action of a potential anti-cancer agent MO2455 in lymphoma cells. 第40回分子病理学研究会クラークシンポジウム: 49, 2023.
12. Gao Z, Tong Y, Saraswat B, Imamichi S, Chen L, Toriya N, Mitsuhashi Y, Sanada Y, Suzuki M, Ishiai M, Masunaga S, Masutani M: Investigation of early expression profiles and functions of SNHG12 after BNCT in tumor cells. 第19回中性子捕捉療法学会学術大会: 2023.
13. Honda N, Tong Y, Vadi Velu A, Saraswat B, Watanabe M, Myat AB, Taniguchi H, Masutani M: Action mechanism of talazoparib as a PARP inhibitor for lung cancer. 第82回日本癌学会学術総会抄録集(Web): 2023.

A-e-2

1. Otaki H, Ishiuchi S, Fujii M, Sugita Y, Yagi K: Similarity scores of vibrational spectra reveal the atomistic structure of pentapeptides in multiple basins. ChemRxiv 10.26434/chemrxiv-2023-qn9rc: 2023. doi: 10.26434/chemrxiv-2023-qn9rc.

B 邦文

B-d

1. 益谷美都子, 木村雄亮, 池内真志: 新型コロナウイルス感染早期診断用ポータブルデバイスの実用化検証. 生体医歯工学共同研究拠点成果報告書 2022年度: 110, 2023.

B-e-1

1. 水谷龍明, 大場雄介, 水田賢志, 浦田秀造: アレナウイルスZ蛋白の自己重合を検出するFRETバイオセンサーの開発と, それを利用した抗ウイルス薬スクリーニング法の確立. 日本蛋白質科学会年会プログラム・要旨集 23rd (CD-ROM): 2023.
2. 佐々木由香, 益谷美都子, 井内拓磨, 中塚隆介, 野崎中成: Olaparib耐性因子探索のためのBRCA1ノックアウトがん細胞株を用いたolaparib耐性クローンの単離. 日本口腔科学会学術集会プログラム・抄録集 77th: 286, 2023.

3. 益谷美都子,今道祥二,Lichao Chen,佐々木由香,小野寺貴恵,中村哲志,増永慎一郎,鈴木 実,井垣 浩,伊丹 純 :
PARP及びPAR代謝経路阻害剤の放射線増感剤としての基礎と臨床応用への課題. 第51回日本放射線腫瘍学会生
物部会学術大会／第60回放射線による制癌シンポジウム : 2023.
4. 佐々木由香,井内拓磨,中塚隆介,益谷美都子,野崎中成 : BRCA1ノックアウト腫がん細胞株におけるolaparib耐性機
序の解析. 第40回分子病理学研究会クラークシンポジウム : 36, 2023.

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2023	10	2	0	1	14	27	10	0	0	0	1	4	5	32

学会発表数一覧

	A-a	A-b シンポジウム	A-b 学会	合計	B-a	B-b シンポジウム	B-b 学会	合計	総計
2023	2	0	0	2	1	0	17	18	20

論文総数に係る教員生産係数一覧

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2023	0.844	9.000	0.370	3.333

Impact Factor値一覧

	Impact Factor	教員当たりのImpact Factor	論文当たりのImpact Factor
2023	33.900	11.300	3.390